News & Updates

Combining the potent first-in-class capsid assembly inhibitor lenacapavir with other antiretroviral agents led to sustained high rates of virologic suppression in treatment-naïve persons with HIV-1 (PWH) infection, according to the week-54 results of the phase II Calibrate trial.

Women with laparoscopically confirmed endometriosis appear to have an elevated risk of early natural menopause (ENM), a recent prospective study has shown.

Ronapreve, also known as REGEN-COV, appears to reduce the risk of hospitalization or the need for additional treatment among COVID-19 patients when used in a real-world setting, a study has shown. The therapy is seen as a promising way to minimize the impact of SARS-CoV-2 infection on the public healthcare system.

Starting vedolizumab early after the diagnosis of ulcerative colitis (UC) appeared more effective than delaying it to after initiation of other UC treatments, according to the RALEE study.

Vaccines provide the best defense against COVID-19, but they are not without limitations. Acute infections still occur in some, especially those who are older, smokers, obese, or with type 2 diabetes (T2D), as reported in a study.

In high-risk nonhospitalized patients with mild-to-moderate COVID-19, intramuscular administration of the monoclonal antibody sotrovimab was noninferior to IV infusion of the drug, according to findings from the phase III COMET-TAIL trial presented at CROI 2022.

While additional tirofiban prior to endovascular treatment (EVT) did not appear to benefit stroke patients with large vessel occlusion (LVO), it did seem to have an advantage for those with large artery atherosclerosis (LAA), findings from the RESCUE BT trial have shown.